Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.05
N/A-2.8213,914 shs5 shs
Harrow, Inc. stock logo
HROW
Harrow
$31.78
+4.0%
$28.32
$20.85
$59.23
$1.17B0.41493,300 shs257,698 shs
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.55
$4.82
$19.50
$97.22M-0.8862,916 shsN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.54
-1.9%
$1.48
$0.63
$1.91
$179.95M-0.05474,044 shs179,781 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-90.00%-99.00%
Harrow, Inc. stock logo
HROW
Harrow
0.00%+2.91%+7.40%+37.64%+43.67%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%0.00%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%+5.49%-38.76%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%-3.75%+7.69%+71.07%+85.54%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
2.6194 of 5 stars
3.52.00.00.02.02.50.6
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
0.7205 of 5 stars
1.00.00.04.20.61.70.6
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.6693 of 5 stars
0.05.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$61.4093.20% Upside
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.50∞ Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TLSA, HROW, OPTN, MDNA, and CALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/19/2025
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.00
5/12/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $60.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
$199.61M5.84$0.14 per share232.19$1.95 per share16.30
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A79.45N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)

Latest TLSA, HROW, OPTN, MDNA, and CALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
Harrow, Inc. stock logo
HROW
Harrow
13.67%
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.67 millionOptionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable

Recent News About These Companies

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Harrow stock logo

Harrow NASDAQ:HROW

$31.78 +1.21 (+3.96%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$31.88 +0.11 (+0.33%)
As of 08:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Medicenna Therapeutics stock logo

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

OptiNose stock logo

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)
As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.54 -0.03 (-1.91%)
Closing price 07/3/2025 03:23 PM Eastern
Extended Trading
$1.54 0.00 (0.00%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.